DJIA 16,501.65 0.00 0.00%
NASDAQ 4,148.34 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
market minute promo

2.48 -0.01 (-0.40%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

CYTX $2.48 -0.40%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.50
Previous Close $2.49
Daily Range $2.38 - $2.53
52-Week Range $2.00 - $3.93
Market Cap $187.1M
P/E Ratio -6.38
Dividend (Yield) $0.00 (0.0%)
Volume 196,187
Average Daily Volume 541,830
Current FY EPS -$0.35

Sector

Healthcare

Industry

Drugs

Cytori Therapeutics, Inc. (USA) (CYTX) Description

A developing company which seeks to commercialize stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and many other serious, chronic, and life threatening conditions. Website: http://www.cytori.com/

News & Commentary

Fast and Furious Health Care Stocks This Week

MannKind, Cytori Therapeutics, and Omeros are among the health care stocks soaring this week.

Cytori Announces Senior Management Changes; Christopher Calhoun CEO and Director of Cytori Therapeut

Cytori Announces Senior Management Changes; Christopher Calhoun CEO and Director of Cytori Therapeutics, is Retiring as CEO of the Company, Effective Immediately

4 Stocks Under $10 Triggering Breakouts

Cytori Therapeutics: Global Patient Stem Cell Demand Builds, Important Short-Term Catalysts Ahead

Cytori Therapeutics Is A Cell Therapy Company With Several Positive Catalysts For 2014

A Glimpse At Our Small Cap Biotechnology Portfolio

Athersys: Why Did Shareholders Come Knocking At The Door Once Again?

Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape

Cytori Therapeutics Inc. (CYTX) Shares March Higher, Can It Continue? - Tale of the Tape

Vical Incorporated (VICL) Jumps: Stock Up 14.5% - Tale of the Tape

Incyte (INCY) Jumps: Stock Rises 6.8% - Tale of the Tape

Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative

Cytori Receives IDE Approval from FDA to Initiate US Clinical Trial of Adipose-Derived Regenerative Cells in Hamstring Injuries

See More CYTX News...

CYTX's Top Competitors

CYTX $2.48 (-0.40%)
Current stock: CYTX
AMGN $113.72 (0.36%)
Current stock: AMGN
GILD $74.08 (0.30%)
Current stock: GILD
BIIB $294.84 (-3.88%)
Current stock: BIIB